logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-12-01 • EBioMedicine
2024-12-01 • EBioMedicine

BACKGROUND

Tar...

Journal Article
|
Research

A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A,  et al.
2024-09-30 • PLOS Neglected Tropical Diseases
2024-09-30 • PLOS Neglected Tropical Diseases

Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. V...

Journal Article
|
Research

Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients

de Vrij N, Pollmann J, Rezende AM, Ibarra-Meneses AV, Pham TT,  et al.
2024-05-03 • Communications Biology
2024-05-03 • Communications Biology
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underl...
Journal Article
|
Pre-Print

HLA-A*03:01 is associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Kassa M,  et al.
2024-02-18 • medRxiv
2024-02-18 • medRxiv
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-H...
Journal Article
|
Commentary

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues

Potet J, Singh SN, Ritmeijer KKD, Sisay K, Alcoba G,  et al.
2022-12-21 • Toxicon: X
2022-12-21 • Toxicon: X
The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each y...
Journal Article
|
Research

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...
Conference Material
|
Poster

Outcomes and effectiveness of antivenom treatments in snakebite patients in north-west Ethiopia: retrospective cohort

Steegemans IM, Sisay K, Nshimiyimana E, Gebrewold G, Piening T,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
Journal Article
|
Research

Treatment outcomes among snakebite patients in north-west Ethiopia—a retrospective analysis

Steegemans IM, Sisay K, Nshimiyimana E, Gebrewold G, Piening T,  et al.
2022-02-09 • PLOS Neglected Tropical Diseases
2022-02-09 • PLOS Neglected Tropical Diseases
BACKGROUND
Millions of people are bitten by venomous snakes annually, causing high mortality and disability, but the true burden of this neglected health issue remains unknown. Since...